Skip to Content Facebook Feature Image

JustMarkets Boost Contest Highlights a Strong Focus on Trader Success

Business

JustMarkets Boost Contest Highlights a Strong Focus on Trader Success
Business

Business

JustMarkets Boost Contest Highlights a Strong Focus on Trader Success

2026-02-07 22:53 Last Updated At:02-08 07:35

HO CHI MINH CITY, Vietnam, Feb. 7, 2026 /PRNewswire/ -- At the end of January, one of the most dynamic trading events of the season, the JustMarkets Boost Contest, officially concluded. The campaign united thousands of active traders worldwide and once again demonstrated how JustMarkets goes beyond standard brokerage services by creating engaging, results-oriented initiatives for its clients.

While many brokers compete solely on spreads and leverage, JustMarkets continues to stand out by combining favorable trading conditions with large-scale events that motivate traders to remain active, disciplined, and consistent.

A Contest Built Around Real Trading

Unlike short-term promotional campaigns focused on short-term spikes in activity, the Boost competition was built on real, consistent trading results. Participation was based on actual trading volume under normal market conditions, encouraging traders to apply strategy, manage risk, and maintain consistency over the long term.

This format ensured that rewards were tied to real market participation, not one-off spikes in activity. Throughout the competition, traders competed in a transparent system in which consistent participation earned valuable prizes.

At the final stage of the campaign, the top participants received prestigious awards, including physical gold trophies that symbolized both their achievements and the growing global interest in precious metals as a store of value.

Weekly Activities That Kept Traders Engaged

One of the contest's defining features was its weekly reward structure. Traders who reached specific trading thresholds were automatically included in regular cash prize draws, creating a steady rhythm of motivation throughout the event.

This balance between short-term incentives and long-term goals helped sustain strong trading activity throughout the contest period. Participants remained engaged not only for the final prizes, but also for the consistent opportunities to be rewarded along the way to the final goal.

Trading Conditions That Made Performance Possible

Behind every successful trading initiative lies a robust trading environment that enables such a comprehensive event to take place and succeed. The JustMarkets Boost Contest demonstrated the advantages of JustMarkets trading infrastructure and solutions, enabling traders to effectively analyze, trade, and perform efficiently even during periods of increased market volatility.

Clients received the following benefits:

  • Competitive and stable spreads
  • Fast and reliable trade execution
  • Flexible leverage options
  • Wide range of tradable instruments, including gold and other popular assets
  • A variety of accounts, including swap-free accounts

Trading conditions and services provide a daily trading environment available to all JustMarkets clients.

A Platform That Rewards Engagement

The conclusion of the Boost Contest highlights a key differentiator in the brokerage market. While many platforms focus solely on trading conditions, JustMarkets combines these fundamental principles with regular initiatives that help traders stay engaged, develop their skills, and discover additional earning opportunities.

Events like the Boost Contest are part of a broader philosophy: trading growth is driven not only by technology and pricing, but also by motivation, education, and community. By integrating these elements into its ecosystem, JustMarkets continues to create an environment where everyone can reach their full investment potential.

For those seeking a trading platform that offers not only competitive conditions but also ongoing initiatives aimed at supporting growth and improving efficiency, JustMarkets remains a standout choice in the global brokerage industry.

Disclaimer: JustMarkets does not provide any investment advice, recommendation, or solicitation to engage in any investment activity. This article is for educational and marketing purposes only and does not contain investment advice or recommendations.

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

JustMarkets Boost Contest Highlights a Strong Focus on Trader Success

JustMarkets Boost Contest Highlights a Strong Focus on Trader Success

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.

Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.

To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.

Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.

The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.

Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.

This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.

These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.

Media Contact: 

Chi Zhang
media@westlake.edu.cn 
+86-15659837873

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform

Recommended Articles